At the end of January, the Ministry of Health announced the second delivery of the results of the National Health Survey (ENS). Among other indicators, it reveals that 25.5 percent of the Chilean population is in the category of high cardiovascular risk. The are many factors and, without a doubt, it is an important challenge that should not only be addressed by the next health authorities, but should be considered in the public policies of the country.
In this scenario, it is necessary to think of innovative treatments that help to alleviate the associated costs, in order to improve their cardiac function and above all, help patients with heart failure to improve their quality of life. With this objective, Chilean researchers from Cells for Cells, a Chilean biotechnology company associated with the Universidad de los Andes, have developed Cellistem®IC, a cell therapy based on mesenchymal cells of the umbilical cord that is administered to the patient intravenously, and ambulatory way. The therapy, whose clinical study was published in the American Heart Association’s Circulation Research Journal, has been administered to patients who showed a significant improvement in their ability to pump blood, and cataloged by specialists as a practical, simple, universal treatment.
In Chile, heart failure affects 16% of the population over 75 years of age, with a mortality that exceeds breast or prostate cancer. Its therapy is limited to pharmacological, surgical and through different devices, such as ventricular resynchronization and the artificial heart, even reaching cardiac transplantation.